Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: Gynecologic oncology group trial 129-P

Journal of Clinical Oncology

Volumn 27, Issue 19, 2009, Pages 3104-3108

  Dizon, Don S ^a   Blessing, John A ^a   McMeekin, D Scott ^a   Sharma, Sudarshan K ^a   DiSilvestro, Paul ^a   Alvarez, Ronald D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIPHENHYDRAMINE; IXABEPILONE; RANITIDINE; ANTINEOPLASTIC AGENT; EPOTHILONE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; CANCER REGRESSION; CLINICAL TRIAL; COHORT ANALYSIS; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; EAR DISEASE; ENDOMETRIUM CANCER; EYE DISEASE; FEMALE; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HUMAN; INFECTION; LEUKOPENIA; LUNG DISEASE; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NEUTROPENIA; OUTCOME ASSESSMENT; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SKIN DISEASE; THROMBOCYTOPENIA; UROGENITAL TRACT DISEASE; VASCULAR DISEASE; DISEASE FREE SURVIVAL; ENDOMETRIUM TUMOR; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; EPOTHILONES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME;

EID: 67650302853     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.6995     Document Type: Article

References (17)

1. American Cancer Society: Cancer Facts and Figures 2007. Atlanta, GA, American Cancer Society Inc, 2007
2. Fleming GF, Brunetto VL, Cella D, et al: Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 22:2159-2166, 2004
3. Randall ME, Filiaci VL, Muss H, et al: Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 24:36-44, 2006
4. Lee FY, Smykla R, Johnston K, et al: Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother Pharmacol 63:201-212, 2009
5. Pivot X, Villanueva C, Chaigneau L, et al: Ixabepilone, a novel epothilone analog in the treatment of breast cancer. Expert Opin Investig Drugs 17:593-599, 2008
6. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
7. Chen TT, Ng TH: Optimal flexible designs in phase II clinical trials. Stat Med 17:2301-2312, 1998
8. Singh M, Zaino RJ, Filiaci VJ, et al: Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: A Gynecologic Oncology Group Study. Gynecol Oncol 106:325-333, 2007
9. Thigpen JT, Blessing JA, Lagasse LD, et al: Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Am J Clin Oncol 7:253-256, 1984
10. Garcia AA, Blessing JA, Nolte S, et al: A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: A study by the Gynecologic Oncology Group. Gynecol Oncol 111:22-26, 2008
11. Lincoln S, Blessing JA, Lee RB, et al: Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 88:277-281, 2003
12. Sutton GP, Blessing JA, Homesley HD, et al: Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium: A Gynecologic Oncology Group study. Cancer 73:1453-1455, 1994
13. Fracasso PM, Blessing JA, Molpus KL, et al: Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 103:523-526, 2006
14. Muggia FM, Blessing JA, Sorosky J, et al: Phase II trial of pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: A Gynecologic Oncology Group study. J Clin Oncol 20:2360-2364, 2002
15. Katsetos CD, Herman MM, Mork SJ: Class III B-tubulin in human development and cancer. Cell Motil Cytoskeleton 55:77-96, 2003
16. Vahdat L: Ixabepilone: A novel antineoplastic agent with low susceptibility to multiple tumor mechanisms. Oncologist 13:214-221, 2008
17. Fomier MN: Ixabepilone, first in a new class of antineoplastic agents: The natural epothilones and their analogues. Clin Breast Cancer 7:757-763, 2007